Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebivolol and Diltiazem for Angina in Myocardial Bridging
NCT04130438Phase 2Terminated
- Sponsor
- Stanford University
- Start
- Oct 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nebivolol, diltiazem in Myocardial bridging (MB), angina pectoris, sponsored by Stanford University. Started Oct 2020; status: terminated.
02
Drugs
nebivololdiltiazem
03
Conditions
Myocardial bridging (MB)angina pectoris
Beyond the preview
Go deeper on NCT04130438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04130438.